Company Overview and News


Add BLUE
to your dashboard

Headline News

Cancer Space Update: Label Expansion for Three Major Drugs

2017-11-17 zacks
With a busy earnings season almost coming to an end after an impressive run, we are again focused on latest cancer updates happening every week. The week gone by saw three cancer drugs receiving FDA approval for new indications – Roche Holding AG’s (RHHBY - Free Report) Gazyva, Pfizer Inc.’s (PFE - Free Report) Sutent and AstraZeneca PLC’s (AZN - Free Report) Faslodex. However, an interesting product in development is a cancer vaccine that Moderna Therapeutics and Merck (MRK - Free Report) are working on. (396-1)

New energy, fresh designs and sustainability at Manila FAME

2017-11-07 lifestyle.inquirer.net
Paper bowl is set amid tableware done in buri, pandan and raffia by PJ Arañador, for the Great Women Project.

Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax, Keryx Ahead Of Catalyst

2017-11-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (692-4)

Small Cap ETFs in Focus as Domestic Growth Picks Momentum

2017-11-02 zacks
U.S. small-caps have been continuously lagging their large-cap counterparts this year. Large-cap stocks have been growing on stepped-up global economy, owing to their high international exposure. Small-cap stocks on the other hand are more domestically focused and exhibit higher volatility than their large-cap counterparts. (41-2)

ROTY Volume 1 Edition 45: More Trades And Updates

2017-11-02 seekingalpha
I finally cut a "loser" from the ROTY model account. While the fundamental thesis appears on track, I can`t ignore the weak technicals any longer. (68-1)

Your Daily Pharma Scoop: Teva Q3 Results, Boost For RedHill, Clovis Reports Rubraca Sales

2017-11-02 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (685-3)

3 Things In Biotech You Should Learn Today: November 2, 2017

2017-11-02 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. (6-0)

A Proven Way To Avoid Bear Markets (Part 3)

2017-11-01 seekingalpha
This is the third chapter in a multi-part series on avoiding bear markets. I will publish a 4th part of the series in a week or so, and perhaps even a 5th part after that if necessary. This chapter describes the general features of three recession-linked risk management models that are available commercially. The next chapter will go into the details of how the models work, and how to use them.

Your Daily Pharma Scoop: Portola's PDUFA, PDLI Makes Some Money, GWPH Completes Rolling NDA

2017-10-31 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (765-3)

Why Earnings Season Could Be Great for bluebird bio (BLUE)

2017-10-30 zacks
Investors are always looking for stocks that are poised to beat at earnings season and bluebird bio, Inc. (BLUE - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. (13-0)

Global Blood Therapeutics: Addressing A Sickle That Impedes Critical Cycling

2017-10-25 seekingalpha
A company leading the race for a new therapy with a drug in Phase III trials. (35-0)

Your Daily Pharma Scoop: Soliris New Indication, Gilead's NASH Data, What Keeps Synergy Down?

2017-10-25 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service. (546-3)

Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider

2017-10-23 zacks
Interest in the CAR-T (chimeric antigen receptor T cells) space continues to build up with the FDA giving its nod to the second CAR-T therapy last week. Gilead Sciences’s (GILD - Free Report) Yescarta, a cell-based gene therapy, gained approval for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. (165-1)

Your Daily Pharma Scoop: AcelRx DSUVIA PDUFA, Ardelyx Phase 3 Success, Rhopressa, LUXTURNA Adcomm Tomorrow

2017-10-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (414-3)

Your Daily Pharma Scoop: MannKind Is A Trade Not An Investment; AstraZeneca's Imfinzi

2017-10-10 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (647-3)